Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights

Core Insights - Alto Neuroscience has reported strong financial results for the year 2025, with a cash balance of approximately $177 million, expected to fund operations into 2028 and support four key data readouts in its precision psychiatry pipeline [1][6][9] Business Highlights - The acquisition of ALTO-207, targeting Treatment-Resistant Depression (TRD), is a significant development, with a Phase 2b trial set to begin in the first half of 2026 [1][3] - The PAX-D study published in The Lancet Psychiatry showed a 0.87 effect size for ALTO-207's core mechanism, indicating a significantly larger effect than current standard treatments [1][4] - ALTO-101 has received FDA Fast Track Designation for Cognitive Impairment Associated with Schizophrenia (CIAS), with topline Phase 2 Proof-of-Concept data expected by the end of Q1 2026 [1][5] Financial Performance - Research and development expenses for 2025 were $45.6 million, a decrease from $47.0 million in 2024, primarily due to the completion of previous studies [8] - General and administrative expenses were $20.7 million in 2025, down from $21.6 million in 2024 [9] - The net loss for 2025 was $63.2 million, compared to a net loss of $61.4 million in 2024, with a net loss per share of $2.19 [9][15] Upcoming Milestones - The Phase 2b trial for ALTO-207 is expected to initiate in the first half of 2026, with topline data anticipated in the second half of 2027 [3][6] - ALTO-300 and ALTO-100 are also in ongoing Phase 2b trials, with topline data expected in mid-2026 and the second half of 2026, respectively [7]